When rosiglitazone treatment was superimposed with PPARγ inhibitor T0070907, the SOD content decreased significantly, while the other biomarkers increased, indicating that rosiglitazone could effectively improve the renal function and protect against CI-AKI, and the inhibition of PPARγ expression might aggravate the injury of CI-AKI to a certain extent. The gene discussed is PPARG; the disease is acute kidney injury.